



1059/2/04


Sheet 1 of 1

Form PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>		<b>Atty. Docket No. (Optional)</b>  16112 (PC25496)	<b>Application Number</b>  10/767,809				
		<b>Applicant(s)</b> Paul J. Dominowski, et al.					
		<b>Filing Date</b> January 29, 2004	<b>Group Art Unit</b> 1643 <i>1645</i>				
<b>U.S. PATENT DOCUMENTS</b>							
<b>EXAMINER INITIAL*</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE (if appropriate)</b>
<b>FOREIGN PATENT DOCUMENTS</b>							
	<b>REF</b>	<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>TRANSLATION</b>
							<b>YES</b> <b>NO</b>
<i>JL</i>		WO 96/33739	10/31/1996	PCT			
<i>JL</i>		0 535 740 A1	4/7/1993	Europe			
<i>JL</i>		1 023 904 A2	8/2/2000	Europe			
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
<i>JL</i>		P. Novotny, et al., "Evaluation of <i>Bordetella Bronchiseptica</i> Vaccines in Specific-Pathogen-Free Piglets with Bacterial Cell Surface Antigens in Enzyme-Linked Immunosorbent Assay", <i>Infection and Immunity</i> , Vol. 50, No. 1 pp. 190-198, (1985)					
<i>JL</i>		P. Novotny, et al, "Adenylate Cyclase Activity of a 68,000-Molecular-Weight Protein Isolated from the Outer Membrane of <i>Bordetella Bronchiseptica</i> ", <i>Infection and Immunity</i> , Vol. 50, No. 1, pp. 199-206, (1985)					
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>					
<i>JL</i>		<i>11/20/04</i>					

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional) 16112 (PC25496)		Application Number 10/767,809			
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		Applicant(s) Paul J. Dominowski, et al.					
		Filing Date January 29, 2004		Group Art Unit Unassigned			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES      NO
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
8.	M. Kobisch, et al., "Identification of a 68-Kilodalton Outer Membrane Protein as the Major Protective Antigen of <i>Bordetella Bronchiseptica</i> by Using Specific-Pathogen-Free Piglets", <u>Infection and Immunity</u> , Vol. 58, No. 2, pp. 352-357, (1990)						
9.	J.A. Montaraz, et al., "Identification of a 68-Kilodalton Protective Protein Antigen from <i>Bordetella Bronchiseptica</i> ", <u>Infection and Immunity</u> , Vol. 47, No. 3, pp. 744-751, (1985)						
10.	C.G. Mackintosh, et al., "The Use of a <i>Hardjo-Pomona</i> Vaccine to Prevent Leptospirosis in Cattle Exposed to Natural Challenge with <i>Leptospira Interrogans</i> Serovar <i>Hardjo</i> ", <u>New Zealand Veterinary Journal</u> , Vol. 28, pp. 174-177						
11.	C.A. Bolin, DVM, PhD, et al., "Effect of Vaccination with a Pentavalent Leptospiral Vaccine on <i>Leptospira Interrogans</i> Serovar <i>Hardjo</i> Type <i>Hardjo-Bovis</i> Infection of Pregnant Cattle", <u>Am. J. Vet. Res.</u> , Vol. 50, No. 1, pp. 161-165, (1989)						
EXAMINER 				DATE CONSIDERED 11/20/06			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. <b>16112 (PC25496A)</b>	
In Re Application Of: <b>Paul J. Dominowski, et al.</b>				
Serial No. <b>10/767,809</b>	Filing Date <b>January 29, 2004</b>	Examiner <b>Unassigned</b>	Group Art Unit <b>Unassigned</b>	
Title: <b>CANINE VACCINES AGAINST BORDETELLA BRONCHISEPTICA</b>				
<div style="text-align: center;"> <p>Address to:</p> <p><b>Commissioner for Patents</b>  <b>P.O. Box 1450</b>  <b>Alexandria, VA 22313-1450</b></p> </div> <div style="text-align: center; margin-top: 10px;"> <p><b>37 CFR 1.97(b)</b></p> </div> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <div style="text-align: center; margin-top: 20px;"> <p><b>37 CFR 1.97(c)</b></p> </div> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <div style="margin-left: 40px;"> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center; margin: 10px 0;"><b>OR</b></p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> </div>				



PTO/SB/08a (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submit for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	10/767,809
Filing Date	January 29, 2004
First Named Inventor	Paul J. Dominowski
Art Unit	1643-1645
Examiner Name	Jennifer E. Graser
Attorney Docket Number	PC25496A

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number * Kind Code <sup>5</sup> (if known)				
		WO90/03184	5 April 1990	Bror Morein		
		Japanese Pat. Pub. No. 6-228010	16 Aug 1994	Biseibutsu Kagaku		

Examiner  
SignatureDate  
Considered

11/20/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Sheet 1 of 2

Form PTO-1449 (REV. 7-80) PATENT AND TRADEMARK OFFICE		U.S. DEPARTMENT OF COMMERCE		Atty. Docket No. (Optional) 16112 (PC25496)		Application Number 10/767,809	
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)				Applicant(s) Paul J. Dominowski, et al.			
				Filing Date January 29, 2004		Group Art Unit Unassigned 1645	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	1.	4,567,042	1/28/86	Acree, et al.			
	2.	4,567,043	1/28/86	Acree, et al.			
	3.	4,824,785	4/25/89	Acree, et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	4.	WO 92/17587	10/15/92	PCT			
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
	5.	R.D. Shahin, et al., "Characterization of the Protective Capacity and Immunogenicity of the 69-kD Outer Membrane Protein of <i>Bordetella Pertussis</i> ", <u>The Journal of Experimental Medicine</u> , Vol. 171, pp. 63-73, (1990)					
	6.	P. Novotny, et al., "Biologic and Protective Properties of the 69-kDa Outer Membrane Protein of <i>Bordetella Pertussis</i> : A Novel Formulation for an Acellular Pertussis Vaccine", <u>The Journal of Infectious Diseases</u> , Vol. 164, pp. 114-122, (1991)					
	7.	Q. He, et al., "Protective Role of Immunoglobulin G Antibodies to Filamentous Hemagglutinin and Pertactin of <i>Bordetella Pertussis</i> in <i>Bordetella Parapertussis</i> Infection", <u>Eur. J. Clin. Microbiol. Infect. Dis.</u> , Vol. 15, No. 10, pp. 793-798, (1996)					
EXAMINER				DATE CONSIDERED 11/20/04			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							